We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced that it has granted Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation, an InterfeRx license to discover, develop, and commercialize an RNAi therapeutic
utilizing a synthetic siRNA, together exclusively with Calando's proprietary delivery technology, that is directed towards a cancer target.
ACell, Inc., the owner of highly valued extracellular matrix (ECM) patents, won a resounding legal victory against Cook Biotech, Inc. (Cook) and Purdue Research Foundation (Purdue).
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, announced that Craig A. Wheeler has been named as the new Chief Executive Officer of Momenta.
In an observational study, researchers found people who take a particular acne medication had higher cholesterol levels than previously thought, although doctors point out the side effects are easily reversible.
The US Food and Drug Administration (FDA) and GlaxoSmithKline notified healthcare professionals of changes to the BOXED WARNING, WARNINGS and PRECAUTIONS sections of the prescribing information for Dexedrine (dextroamphetamine sulfate), approved for the treatment of Attention-Deficit Hyperactivity Disorder and narcolepsy.
Encysive's drug Argatroban, approved to prevent blood clots in heart attack victims, may also help open blocked arteries in stroke patients, according to a study published in the Aug. 14 issue of Archives of Neurology.
A patient who suffered gastrointestinal (GI) bleeding during a clinical trial prompted the FDA to send a warning letter to the clinical investigator, Evangeline Gonzalez of Gonzalez Internal Medicine.
Barr Pharmaceuticals may be only weeks away from FDA approval to sell its controversial contraceptive Plan B OTC after resubmitting its application and apparently meeting all the agency's demands.